Centene Corp. has offered voluntary buyouts to the majority of its employees following a significant decline in membership across its health plans. The U.S. insurer launched a voluntary separation program allowing eligible employees to apply for buyouts, though participation is subject to company approval. The move aims to reduce costs after the company experienced the most significant enrollment losses in its Affordable Care Act (ACA) marketplace business.

Centene employed approximately 61,000 people during the first quarter. While the company did not disclose how many positions it hopes to eliminate, it indicated that additional workforce reductions could occur if voluntary departures do not meet internal targets. The strategic shift is a direct response to financial pressure resulting from the loss of members, specifically driven by the expiration of pandemic-era federal subsidies.

Membership in ACA plans fell by roughly 2 million this year. The decline followed Congress allowing COVID-era subsidies to expire, resulting in higher costs for many consumers purchasing coverage through ACA marketplaces. During the first quarter, total membership across Centene's portfolio declined to 26.27 million from 27.9 million a year ago. Marketplace membership specifically fell from 5.626 million to 3.582 million in the first quarter.

Membership Trends and Guidance

At the Barclays Global Healthcare Conference in March, Centene flagged lower membership in some ACA plans. The company noted that ACA membership attrition would shrink somewhere between the high teens and the mid-30s. "But we were pretty consistent in the view that we would be at the higher end of that and possibly higher than the top end of that, partly because of our FPL mix and partly because of the pricing actions that we took coming into the year and our focus on margin over membership," said Sarah London, Centene's CEO.

First Quarter Membership Overview

The company's move highlights the broader challenges within the healthcare insurance sector as market dynamics shift under current policy frameworks.

Mizuho analyst Ann Hynes has maintained a Neutral rating on Centene (NYSE: CNC) while raising the price target to $63 from $58. The revised target indicates an updated valuation perspective following a review of the company's financial position and market conditions.

The decision to retain the Neutral stance suggests that the stock's risk-reward profile remains balanced at the new price level. The increase in the price target points to a modest improvement in the company's projected performance relative to previous estimates.

Centene operates as a major healthcare enterprise, and its stock performance is closely tied to regulatory changes and healthcare policy developments. The new price target of $63 represents a specific level where the firm believes the shares should trade over the medium term.